Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) EPS (Weighted Average and Diluted) (2021 - 2025)

iBio (IBIO) has disclosed EPS (Weighted Average and Diluted) for 10 consecutive years, with -$0.08 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 83.33% to -$0.08 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.0, a 28.21% decrease, with the full-year FY2025 number at -$1.75, up 73.08% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.08 for Q4 2025 at iBio, up from -$0.11 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $64.85 in Q1 2023 to a low of -$108.8 in Q4 2022.
  • A 5-year average of -$3.13 and a median of -$0.64 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 7841.61% in 2022, then skyrocketed 8522.08% in 2023.
  • iBio's EPS (Weighted Average and Diluted) stood at -$1.37 in 2021, then tumbled by 7841.61% to -$108.8 in 2022, then soared by 97.78% to -$2.42 in 2023, then soared by 80.17% to -$0.48 in 2024, then soared by 83.33% to -$0.08 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's EPS (Weighted Average and Diluted) are -$0.08 (Q4 2025), -$0.11 (Q3 2025), and -$0.31 (Q2 2025).